Skip to content
PICO Portalanswers from OpenAlex

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease

PaperCitations, authors & open-access status

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease is a paper indexed in PICO Portal from OpenAlex.

How many citations does Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease have?

PICO Portalcitation count

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease has 147 citations in the OpenAlex counts PICO Portal stores.

When was Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease published?

PICO Portalyear

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease has 2018 year in the PICO Portal index.

What is the open-access status of Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease?

PICO Portaloa status

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease has closed oa status in the PICO Portal index.

What is the DOI of Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease?

PICO Portaldoi

The DOI for Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease is on the source record.

What is the PMID of Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease?

PICO Portalpmid

The PMID for Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease is on the source record.

What is the OpenAlex record for Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease?

PICO Portalopenalex

The OpenAlex for Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial